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Purpose. The aim of this study was to develop microspheres with an ultra high holmium content which
can be neutron activated for radioablation of malignancies. These microspheres are proposed to be
delivered selectively through either intratumoral injections into solid tumors or administered via an
intravascularly placed catheter.
Methods. Microspheres were prepared by solvent evaporation, using holmium acetylacetonate
(HoAcAc) crystals as the sole ingredient. Microspheres were characterized using light and scanning
electron microscopy, coulter counter, titrimetry, infrared and Raman spectroscopy, differential scanning
calorimetry, X-ray powder diffraction, magnetic resonance imaging (MRI), and X-ray computed
tomography (CT).
Results. Microspheres, thus prepared displayed a smooth surface. The holmium content of the HoAcAc
microspheres (44% (w/w)) was higher than the holmium content of the starting material, HoAcAc
crystals (33% (w/w)). This was attributed to the loss of acetylacetonate from the HoAcAc complex,
during rearrangement of acetylacetonate around the holmium ion. The increase of the holmium content
allows for the detection of (sub)microgram amounts of microspheres using MRI and CT.
Conclusions. HoAcAc microspheres with an ultra-high holmium content were prepared. These
microspheres are suitable for radioablation of tumors by intratumoral injections or treatment of liver
tumors through transcatheter administration.
KEY WORDS: holmiumacetylacetonate; intratumoral; microspheres; multimodality; radioablation.
INTRODUCTION
Worldwide, primary liver cancer (hepatocellular carcino-
ma or cholangiocarcinoma) is the sixth most common cancer,
and each year over 600,000 new cases are presented. A
limited number of patients is eligible for surgical resection
(partial hepatectomy or liver transplantation), limiting the
5 year survival rate to only 3–5% (1,2). The use of systemic
chemotherapy has been proven ineffective, however recently
a survival benefit of several months has been reported for the
oral multikinase inhibitor sorafenib (3).
The liver is also a common site of metastasis, and more
than 50% of patients with primary malignancies will develop
hepatic metastases. A very common type of cancer to
metastasize solely to the liver is colorectal carcinoma. Each
year over 1,000,000 new cases of colorectal cancer are
presented and the mortality is approximately 500,000 patients
per year. Five year survival of patients in the developed world
with colorectal cancer is approximately 55%, with main
prognostic factors being the extent of lymphatic spread, the
number and resectability of liver metastases (1,2). Surgical
resection, considered to be the only curative treatment
option, is only eligible in 10% to 20% of patients (4).
Currently applied chemotherapy protocols (e.g. FOLFOX or
FOLFORI, 5-fluorourcil/leucovorin combined with oxalipla-
tin or irrinotecan, respectively, in combination with the
angiogenesis inhibitor bevacizumab) are associated with a
survival of patients with unresectable liver metastases of
nearly 2 years (5,6).
Intra-arterial radioembolisation with radioactive micro-
spheres (glass- or resin-based) containing the high-energy
beta emitter yttrium-90 (90Y) is currently increasingly applied
in patients with unresectable hepatic malignancies. This 90Y
radioembolisation treatment has shown very high response
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rates (up to 91%), in both salvage setting and as a first-line
treatment option (7,8). The lack of (quantitative) imaging
options for 90Y (9) has lead to the development of holmium-
166 loaded poly(L-lactic acid) (166HoPLLA)microspheres, since
166Ho emits gamma rays and beta particles that can be used for
nuclear imaging and therapy, respectively (10–12). Moreover,
holmium is highly paramagnetic and has a high linear
attenuation coefficient allowing for visualization by magnetic
resonance imaging (MRI) and X-ray computed tomography
(CT), respectively (13,14).
Unfortunately, restrictions to inclusion to this intra-
arterial transcatheter radioembolisation approach exist. For
example, in patients who have been heavily pretreated with
bevacizumab or cetuximab, the tumor feeding vessels may be
too feeble for the microspheres to be deposited peri- and
endotumorally (15). Efficacy may also be diminished in
patients with hypovascular liver tumors. Furthermore,
patients with portal vein thrombosis are excluded from
treatment with the resin microspheres (16). Extensive liver
cirrhosis and poor general health may also hamper the use of
this treatment option.
Especially in patients with a limited number of unresectable
intrahepatic tumors, not eligible for transcatheter radioemboli-
sation, intratumoral injections of radioactive microspheres
might be an option. This approach has been explored in patients
with liver tumors using 90Y glass microspheres, showing a
response rate in 90% of patients (17). Direct intratumoral
injection requires small deposits of radioactive microspheres in
compact tumor tissue, limiting the overall injection volume to
0.1–0.3 ml (17,18). Consequently, the amount of activity per
injection should be very high.
The purpose of this study was to prepare holmium
loaded microspheres, using holmium acetylacetonate (HoA-
cAc) crystals as the sole staring material, without the use of
PLLA as matrix forming polymer, to increase the content of




All chemicals are commercially available and were used as
obtained. Acetylacetone (2,4-pentanedione, AcAc; >99%),
ammoniumhydroxide (NH4OH; 29.3% in water), chloroform
(HPLC-grade), phosphorus pentoxide (Sicapent®), polyvinyl
alcohol (PVA, average MW 30,000–70,000) and Pluronic F68®
(PEO100PPO65PEO100; MW9,840-14,600) were purchased from
Sigma Aldrich (Steinheim, Germany). Holmium CertiPUR ICP
standard and hexamethylentetramine were purchased from
Merck (Darmstadt, Germany). Seakem LE Agarose was
purchased from Lonza (Basel, Switzerland). Holmium (III)
chloride hexahydrate (HoCl3.6H20; 99.95%) was purchased
from Metall Rare Earth Ltd (Shenzhen, China).
Preparation of HoAcAc Microspheres
The holmium acetylacetonate microspheres (HoAcAc
MS) were prepared using a solvent evaporation process.
Holmium acetylacetonate crystals were prepared as previous-
ly described by Nijsen et al. (10). HoAcAc crystals were
dissolved in chloroform (186 g, 5.5% (w/w)) and emulsified in
an aqueous PVA solution (1 l, 2% (w/w)). The chloroform/
water emulsion was continuously stirred at a preset stirring
speed (300–500 rpm). To evaporate chloroform, the mixture
was thermostated at 25°C and a constant flow of nitrogen
(12 l min−1) was applied. After 40 h of evaporation the
formed microspheres were collected by centrifugation and
washed five times with water. The washed microspheres were
sieved using an electronic sieve vibrator, (EMS 755) and
ultrasonic processor (UDS 751; Topaz GmbH, Dresden,
Germany) as described by Zielhuis et al. (19). The
microspheres were dried at room temperature for 24 h,
followed by drying at 50°C for 48 h.
Size Distribution, Holmium Content
and Surface Characteristics
The size distribution of the sieved fractions and dried
fractions was determined using a Coulter counter (Multisizer
3, Beckman Coulter, Mijdrecht, The Netherlands), equipped
with an orifice of 100 μm.
The holmium content of the microspheres was deter-
mined by complexometric titration with EDTA as described
by Zielhuis et al. (19), and Inductively Coupled Plasma
Optical Emission spectroscopy (ICP OES). Samples were
measured at three different wavelengths (399.989; 345.600
and 347.426 nm) in an Optima 4300 CV (PerkinElmer;
Norwalk, USA).
Elemental analysis of carbon, hydrogen, oxygen and
holmium of the HoAcAc crystals and HoAcAc microspheres
was performed by H. Kolbe, Mülheim an der Ruhr, Germany.
SEM micrographs were acquired using a FEI PHENOM
(FEI Company, Eindhoven, The Netherlands) electron mi-
croscope. Samples were mounted on an aluminum stub, and
coated with a Pt layer of 6 nm.
Raman Spectroscopy
Raman spectroscopy was performed on a Kaiser RXN
spectrometer equipped with a 70 mW 785 nm diode laser for
excitation, a holographic grating for dispersion and a Peltier
cooled Andor CCD camera for detection.
Differential Scanning Calorimetry
Modulated Differential Scanning Calorimetry (mDSC)
measurements were performed using a DSC Q1000 (TA
Instruments Inc., New Castle, DE, USA). The modulation
amplitude was set at 1°C min−1. Samples were heated from 20°C
to 220°C with a heating rate of 2°C min−1.
X-ray Diffraction
X-ray diffraction patterns were obtained on a Nonius κ-
CCD diffractometer, with a sealed tube using MoKα radia-
tion with a graphite monochromator. Powder patterns were
recorded to a maximum scattering angle (2θ) 22°. The
samples were contained in boroglass capillaries.
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Neutron Activation
Neutron activation was performed in the pneumatic
rabbit system operational at a research reactor facility
(Department of Radiation, Radionuclides and Reactors,
Delft University of Technology, Delft, The Netherlands).
Samples were irradiated for 3 or 6 h with a thermal neutron
flux of 5×1012 n cm−2 s−1. The radioactive 166Ho was left to
decay for 1 month, to ensure safe handling of HoAcAc
microspheres.
Multimodality Imaging Characteristics
To determine the sensitivity of MRI and CT for the
HoAcAc microspheres, phantom experiments were carried
out on MRI and CT. The phantom used to determine MRI
and CT sensitivity consisted of agarose (2% (w/w)) gel
samples in which HoAcAc microspheres were homogeneous-
ly dispersed (loadings ranged from 0 to 4 mg microspheres
per ml agarose) in plastic tubes (diameter 10 mm, length
100 mm). MR imaging was performed using a 1.5 T clinical
MR scanner (Intera, Philips Medical Systems, Best, The
Netherlands). To determine the r2* relaxivity, which repre-
sents the MR sensitivity of the HoAcAc microspheres,
transverse images were made using a multiple gradient echo
MR sequence with 15 echos, an echo spacing of 1.39 ms a
repetition time of 500 ms, a field of view (FOV) of 128 mm, a
voxel size of 1×1×10 mm, two signal averages and a 60° flip
angle. Monoexponential signal decay was assumed. Data
processing was performed as described by Seevinck et al. (14).
A second agarose gel phantom was constructed for qualita-
tive imaging. This gel consisted of 2% (w/w) agarose, with
pockets for the administration of a suspension of HoAcAc
microspheres to obtain depots of 1 µg to 1 mg. The imaging
parameters were similar to the imaging parameters men-
tioned before, except for the slice thickness, which was 1 mm.
To mimic potential in vivo imaging applications, depots
of HoAcAc microspheres were injected in an ex vivo rabbit
liver. The excised liver was flushed with water, and placed in
an aqueous solution containing MnCl2 (19.2 mg/L), to reduce
the relaxation time of the water. Fifty microlitre of a
suspension of HoAcAc microspheres was administered to
the liver, to obtain depots of 1, 5 and 10 μg microspheres. The
imaging parameters were similar to the imaging parameters
mentioned before. For the MR images displayed in Fig. 5A,
D, E and F an echo time of 20 ms was used.
Quantitative X-ray CT imaging was performed on a
clinical 64 slice CT scanner (Brilliance, Philips Medical
Systems, Best, The Netherlands). The sample tubes were
positioned co-axially to the main axis of the scanner. Using
the methods described by Seevinck et al, a linear regression
curve was constructed to determine the sensitivity of X-ray
CT for HoAcAc microspheres (14).
RESULTS AND DISCUSSION
Size Distribution, Holmium Content and
Surface Characteristics
We found that HoAcAc microspheres could be obtained
of HoAcAc crystals without using PLLA as a matrix forming
polymer using a solvent evaporation technique.
The size distribution, surface morphology of the micro-
spheres were characterized using Coulter Counter, light
microscopy and scanning electron microscopy (SEM), both
before and after neutron activation. The particle size
distribution was rather broad, from 5 to 40 μm, with an
average microsphere size of 15 μm when the microspheres
were prepared at 500 rpm. The average particle size could be
tailored by altering the stirring rate during emulsifying and
increased from 15 μm at 500 rpm to 20 μm at 400 rpm and
26 μm at 300 rpm. The size distribution should be narrow to
control the biodistribution of the microspheres and to reduce
possible shunting of small microspheres to non-target organs
after administration. Therefore, a sieving step is necessary to
obtain a more confined size distribution. More than 93% of
the microspheres had a size between 15–20 μm after sieving.
No changes in microsphere size distribution were observed
after neutron activation, which is an indication that small
fragments due to radiation damage were absent. Light and
scanning electron microscopy showed that spherical particles
with a smooth surface were formed (Fig. 1A and B). Neither
surface damage nor agglomeration was observed after
neutron activation of the microspheres. After neutron activa-
tion for 3 or even 6 h, the surface of the microspheres only
showed small crevices. However, no large fragments were
present (Fig. 1C). This, in combination with the size
Fig. 1. A Light micrograph of HoAcAcmicrospheres before sieving (mean size 15 µm),B scanning electron micrograph of non
activated HoAcAc microspheres and C scanning electron micrograph of HoAcAc microspheres after 6 h of neutron activation.
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distribution results, indicates that the microspheres are
resistant to neutron irradiation.
The holmium content of the HoAcAc microspheres, as
determined by complexometric titration, ICP OES and
elemental analysis was found to be 45.0±0.5% (w/w), which
is significantly higher than the holmium content of the
HoAcAc crystals, being 31.2% (w/w) (Table I). Also, the
density of the HoAcAc microspheres (1.90 g/ml) was higher
than the density reported for HoAcAc crystals (1.77 g/ml
(20)). In the HoAcAc crystals, holmium is surrounded by
three acetylacetonate ligands, and three water molecules
(10,20). The increase in holmium content of the HoAcAc
microspheres was explained by a loss of one or more
acetylacetonate ligands caused by a structural rearrangement
of the acetylacetonate ligands around holmium. This hypoth-
esis was further investigated by determining the elemental
composition of the microspheres and Raman spectroscopy.
The substantially higher holmium content per sphere
(17.0% (w/w) for the HoPLLA microspheres vs. 45.0% (w/w)
for the HoAcAc microspheres) results in a significant
increase in radioactivity per sphere from 29 MBq/mg for
HoPLLA microspheres (12) to 76 MBq/mg for HoAcAc
microspheres (6 h neutron activation; thermal neutron flux of
5×1012 n cm−2 s−1). Clinical results after intratumoral
injection of 90Y glass microspheres showed that 74 MBq 90Y
is sufficient to evoke a tumoricidal effect on a tumor of 3 cm
(17). The injected volume of the microsphere suspension to
such a tumor is limited to typically 0.1–0.3 ml (18). Based on
the radiation characteristics of 166Ho and 90Y it can be
calculated that a tumoricidal dose of 166Ho activity
(230 MBq/3 mg) can be delivered in this volume using
HoAcAc microspheres for intratumoral administration (12).
Raman Spectroscopy
Infrared and Raman spectroscopy was performed to
ascertain the presence of acetylacetonate in the microspheres.
The Raman spectra of the HoAcAc crystals and the HoAcAc
microspheres were virtually identical (Fig. 2), which implies
that holmium is surrounded by acetylacetonate in both the
HoAcAc crystals and the HoAcAc microspheres. These
findings are in agreement with the infrared measurements
on HoAcAc microspheres that showed the same peak
characteristics as for HoAcAc crystals previously reported
(21). The increase of the holmium content, found by
elemental analysis, complexometric titration and ICP OES
can therefore only be explained by a rearrangement of
acetylacetonate groups around the holmium(III) ion. Taking
into account that holmium is surrounded by acetylacetonate
ligands, and the results from the elemental analysis (Table I),
we propose that per holmium ion one and a half acetylacet-
onate and two water molecules are present in the HoAcAc
microspheres. The change of the acetylacetonate coordina-
tion should, in principle, be reflected in an intensity decrease
of the Ho–O bending band, but since the position of this
vibration is expected around 100 cm−1 (22), it is most likely
filtered out with the Rayleigh scattering. The hypothesized
structure of the HoAcAc microspheres is depicted in Fig. 3.
As can be seen in this figure, acetylacetonate forms a bridge
between two holmium(III) ions by coordinating each carbonyl
to another holmium(III) ion forming a network. This bridging
effect of chelates between metal ions has been proposed for
metal catalysts after gradual removal of the solvent (23). The
water observed in elemental analysis (Table I) is likely
coordinated to the holmium(III) ion, as previously reported
for HoAcAc crystals (20). An important observation that
supports the network formation between holmium and
acetylacetonate is that HoAcAc microspheres, in contrast to
HoAcAc crystals, did not dissolve in chloroform.
Differential Scanning Calorimetry
The thermal behaviour of HoAcAc crystals and HoA-
cAc microspheres was investigated using modulated differen-
tial scanning calorimetry (mDSC). Representative mDSC
scans of the holmium acetylacetonate crystals and micro-
spheres are shown in Fig. 4, and relevant data are summa-
Fig. 2. Raman spectra of HoAcAc microspheres (solid line) and
HoAcAc crystals (dotted line).
Table I. Calculated and Measured Elemental Composition of HoAcAc Crystals and Proposed and Measured Composition of HoAcAc
Microspheres (in % w/w)
Element
HoAcAc Crystals Ho(AcAc)3•3H2O HoAcAc Microspheres Ho2(AcAc)3•4H2O
Calculated Measureda Proposedb Measured
C 34.9 36.5 25.8 27.0
H 5.3 5.0 4.2 3.8
O 27.9 27.1 22.9 24.2
Ho 31.9 31.2 47.2 45.0
aData taken from Nijsen et al. (10)
b Structure of HoAcAc microspheres is proposed based on measured elemental composition and Raman spectroscopy
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rized in Table II. The thermogram for HoAcAc crystals
shows an endotherm with a peak maximum at 123±7°C. This
endotherm was ascribed to the loss of water from the
complex, leading to the collapse of the crystalline structure
of the crystals (21). HoAcAc microspheres show a distinctly
different thermogram. We observed an endotherm at approx-
imately 194±2°C, which is likely due to the loss of water from
the structure. Interestingly, after heating to 200°C the micro-
spheres were still intact, and the surface of the microspheres
showed minor signs of damage. In contrast, heating of the
HoAcAc crystals to 200°C lead to completely molten material,
which is in agreement with literature (24). The resistance of
microspheres to heating to 200°C is also an indication that a
network is formed. Moreover, this resistance to heat allows for
dry heat sterilization (25), making the microspheres suitable
for in vivo use. DSC analysis of neutron activated HoAcAc
microspheres showed an endotherm at 199±3°C, which is
likely associated with the loss of water, which was also
observed for the non activated microspheres.
X-ray Diffraction
The internal structure of the HoAcAc crystals and
HoAcAc microspheres was studied using X-ray diffraction.
The HoAcAc crystals have a crystalline structure (21), with a
powder pattern reflecting the periodicity of the crystal
structure. The pattern for the HoAcAc microspheres shows
no sharp peaks at a higher diffraction angle. This indicates the
absence of repetitive intermolecular interactions, which is
typical for amorphous structures. The broad peak in the
HoAcAc microsphere diffraction pattern at a diffraction
angle of approximately 11° can be attributed to the distance
of two holmium atoms separated by one acetylacetonate
molecule, which is approximately 4.5 Å. Since holmium has a
large scattering power due to the relatively high number of
electrons, the high intensity peak at a diffraction angle of
approximately 3.2° is ascribed to the Ho–Ho contact in its
amorphous form, corresponding to a bond length of approx-
imately 15.5 Å (21).
Multimodality Imaging Characteristics
The paramagnetic nature and the high linear attenuation
coefficient of holmium allows for multimodality imaging of
non-radioactive HoPLLA microspheres.
To investigate if the multimodality imaging character-
istics enhanced with an increase of the holmium concentra-
tion, the HoAcAc microspheres were homogeneously
dispersed in an agarose gel matrix. The paramagnetic nature
of holmium locally induces a magnetic field inhomogeneity,
leading to an enhanced MRI signal decay in gradient echo
images (13). The resulting r2* relaxivity of the HoAcAc
microspheres with a holmium load of 45% (w/w), is 264±
5.7 s−1 mg−1 ml, which is substantially higher than the r2*
value for the HoPLLA microspheres with a holmium load of
17% (w/w) (92±3.2 s−1 mg−1 ml) (26). This increase of the r2*
relaxivity represents an enhanced sensitivity of MRI to the
HoAcAc microspheres, as compared with HoPLLA
microspheres, which can be explained by the increased
holmium weight content per sphere.
Quantitative CT of the agarose phantom resulted in a mass
attenuation coefficient at 120 kV of 15.6 HU mg−1 ml for
HoAcAc MS, which is substantially increased, when compared
to the mass attenuation coefficient of HoPLLA microspheres of
6.7 HU mg−1 ml at 120 kV (14). This increase in CT sensitivity,
like the increase of sensitivity of MRI to the HoAcAc
microspheres, can be attributed to the increase in holmiumcontent.
To demonstrate the feasibility of visualization of micro-
gram amounts of HoAcAc microspheres, using MRI and CT,
decreasing amounts of HoAcAc microspheres (1 mg to 1 µg)
in clusters were imaged in vitro as well as ex-vivo. The
enhanced r2* relaxivity of the HoAcAc microspheres allowed
for the detection of 1 µg of HoAcAc microspheres in the gel
(Fig. 5A). The same setup was used for CT measurements,
and the increased Ho content per sphere resulted in detection
Fig. 3. The proposed interaction of acetylacetonate with holmium
(III) ion in HoAcAc microspheres (coordinated water molecules not
shown). Each acetylacetonate carbonyl oxygen coordinates with a
separate holmium(III) ion, linking two holmium(III) ions.




HoAcAc Crystals 118±7 123±7 115±9
HoAcAc Microspheres 188±2 194±2 25±5
Neutron activated HoAcAc Microspheres 190±3 199±3 12±11
aOnset Tmax: onset of the endotherm
b Tmax: peak maximum of the endotherm
cΔH: enthalpy of the endotherm
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of 50 μg HoAcAc microspheres (Fig. 5B and C). We used an
excised rabbit liver (Fig. 5D), with depots of 1, 5 and 10 µg
HoAcAc microspheres to investigate the ex-vivo imaging
characteristics on MRI. The inhomogeneity of the ex-vivo
rabbit liver resulted in the detection of depots from 5 µg
onwards (Fig. 5E and F).
Unlike the 90Y microspheres, which lack the MR imaging
possibilities, holmium microspheres can be visualized directly
therefore allow for tracking of the microspheres long after the
radioactive 166Ho has decayed, and thus establish the in vivo
fate of the microspheres after intratumoral injection in a non
invasive manner using MRI. The detection of microgram
amounts of HoAcAc microspheres will also enable MRI
guided administration of the particles, allowing for accurate
positioning of the depots in tumor tissue, whilst refraining
healthy tissue from radiation damage.
Clinical Perspective
The two currently available 90Y microspheres are glass-
based (Therasphere®, MDS Nordion, Kanata, Canada) or
resin-based (SIR-Spheres®, SIRTeX Medical Ltd., Sydney,
Australia). The glass microspheres have a very high specific
activity (2.5 kBq/microsphere), and are registered as a
Humanitarian Use Device by the FDA for use in radiation
treatment or neoadjuvant to surgery or transplantation in
patients with unresectable hepatocellular carcinoma (27). The
resin based microspheres have a relatively low specific
activity 40 Bq/sphere, and were granted premarket approval
by the FDA in 2002 (27).
With regard to the transcatheter approach, the HoAcAc
microspheres might be considered for treatment of patients
with hypovascular liver malignancies. This is due to the
specific activity of the 166HoAcAc microspheres which is in
Fig. 5. AGradient echoMRI image of agarose phantom with different depots of HoAcAc microspheres, B CT image of agarose
phantom with different depots of HoAcAc microspheres, C schematic representation of agarose phantom with different depots of
HoAcAc microspheres, including the amount of microspheres in milligram,DMRI image of rabbit liver before administration of
HoAcAcmicrospheres,EMRI image of rabbit liver after administration of 5 µgHoAcAcmicrospheres, indicated by arrow,FMRI
image of rabbit liver after administration of 10 µg HoAcAc microspheres, indicated by arrow.
Fig. 4. mDSC thermograms of A holmium acetylacetonate crystals, B
holmium acetylacetonate microspheres and C neutron activated (6 h)
holmium acetylacetonate microspheres. Tmax is the maximum peak of
the endotherm.
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the range of the specific activity of the glass 90Y microspheres.
The obvious advantage of the 166HoAcAc microspheres lies
in multimodality imaging.
Moreover, the high specific activity of the 166HoAcAc
microspheres will allow for the delivery of a tumoricidal dose
through intratumoral injections. This approach is thought to
be applicable not only in patients with liver malignancies, but
also in patients with solid tumors in other organs, e.g. brain,
kidney and lungs.
However, before a phase I clinical study is allowed to be
conducted, several issues need to be addressed. First the
pharmaceutical quality needs to be investigated, e.g. stability
testing. Secondly, the in vivo toxicity needs to be assessed.
The toxicity is expected to be minor, since holmium is a
relatively non toxic metal (28). Finally, the therapeutic
efficacy of the 166HoAcAc microspheres needs to be
evaluated in tumor bearing animals.
CONCLUSION
In conclusion, the present study demonstrates that
microspheres with an ultra high holmium content can be
prepared from HoAcAc crystals as the sole starting material,
without the use of a polymeric matrix, using a solvent
evaporation process. The resulting microspheres have a
smooth surface, and are resistant to neutron activation with
a thermal neutron flux (5×1012 n cm−2 s−1) and heating to
200°C. The mean particle size can be tailored for different
tumor treatment approaches by adapting the processing
parameters. The size increased from 15 to 26 µm when
lowering the stirring rate from 500 to 300 rpm during
emulsifying. The HoAcAc microspheres have an unex-
pectedly high holmium content of 45% (w/w) which is
substantially higher when compared to the HoPLLA
microspheres (17% (w/w)). Moreover, the holmium content
in HoAcAc microspheres is higher than in the HoAcAc
crystals (31% (w/w)), which is attributed to a rearrangement
of acetylacetonate molecules around the holmium(III) ion,
resulting in the loss of one and a half coordinating
acetylacetonate molecules per holmium(III) ion. The data of
this study suggest that acetylacetonate acts as a bridge
between holmium(III) ions, forming an amorphous network.
The increased holmium content leads to a 2.6 fold higher
radioactivity per sphere (29 MBq/mg for HoPLLA
microspheres vs. 76 MBq/mg for HoAcAc microspheres),
which allows for tumoricidal radioactive doses in small
volumes necessary for direct intratumoral injection. Ad-
ditionally, the increased holmium content leads to a higher
sensitivity for MRI and CT imaging, enabling detection of
microgram amounts of microspheres in vivo.
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